Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $4.00.

TNYA has been the topic of several recent analyst reports. Weiss Ratings upgraded Tenaya Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Wall Street Zen cut shares of Tenaya Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 29th.

Tenaya Therapeutics Stock Performance

Shares of NASDAQ:TNYA opened at $0.68 on Friday. The company has a market capitalization of $153.19 million, a PE ratio of -1.29 and a beta of 2.77. The stock has a fifty day moving average of $0.76 and a 200-day moving average of $0.75. Tenaya Therapeutics has a one year low of $0.53 and a one year high of $2.35.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its earnings results on Wednesday, August 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.13). The firm had revenue of $1.11 million during the quarter, compared to the consensus estimate of $10.00 million. As a group, research analysts forecast that Tenaya Therapeutics will post -0.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Tenaya Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Integrity Wealth Solutions LLC acquired a new stake in Tenaya Therapeutics during the 1st quarter valued at $27,000. Scientech Research LLC purchased a new stake in shares of Tenaya Therapeutics in the third quarter valued at $27,000. Callan Family Office LLC acquired a new stake in shares of Tenaya Therapeutics in the second quarter worth $37,000. Comerica Bank acquired a new stake in shares of Tenaya Therapeutics in the first quarter worth $50,000. Finally, Cerity Partners LLC grew its holdings in shares of Tenaya Therapeutics by 403.5% during the second quarter. Cerity Partners LLC now owns 110,336 shares of the company’s stock valued at $67,000 after buying an additional 88,424 shares in the last quarter. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics is a clinical?stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno?associated virus (AAV) platform, the company aims to deliver durable, one?time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.